Development of PROTACs using computational approaches

被引:4
|
作者
Ge, Jingxuan [1 ,2 ]
Hsieh, Chang-Yu [1 ]
Fang, Meijing [3 ]
Sun, Huiyong [4 ]
Hou, Tingjun [1 ,3 ]
机构
[1] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China
[2] CarbonSilicon AI Technol Co Ltd, Hangzhou 310018, Zhejiang, Peoples R China
[3] Zhejiang Univ, Polytech Inst, Hangzhou 310058, Zhejiang, Peoples R China
[4] China Pharmaceut Univ, Dept Med Chem, Nanjing 210009, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
PROTEIN-DEGRADATION; PREDICTION; COMPLEX; UBIQUITINATION; KNOCKDOWN; MOLECULES; DISCOVERY; RESOURCE;
D O I
10.1016/j.tips.2024.10.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Proteolysis-targeting chimeras (PROTACs) are drugs designed to degrade target proteins via the ubiquitin-proteasome system. With the application of computational biology/chemistry technique in drug design, numerous computer-aided drug design and artificial intelligence (AI)-driven drug design (CADD/AIDD) methods have recently emerged to facilitate the development of PROTAC drugs. We systematically review the role of in silico tools in PROTAC drug design, emphasizing how computational software can model PROTAC action and structure, predict activity, and assist in molecule design. We also discuss current challenges in the rational design of PROTACs from an in silico perspective, such as deviations from small-molecule druggability and the limited availability of training data. We provide an overview of recent discoveries and emerging research in this field, and discuss their potential impact on PROTAC design strategies.
引用
收藏
页码:1162 / 1174
页数:13
相关论文
共 50 条
  • [41] Development of PROTACs for targeted degradation of MALT1
    Jones, D.
    Gibbs, W.
    Ambler, M.
    Crompton, C.
    Saxty, B.
    Newman, M.
    Ansell, K.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E122 - E122
  • [42] Development of visible-light-activatable photocaged PROTACs
    Weng, Weizhi
    Xue, Gang
    Pan, Zhengying
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 265
  • [43] Development of a PDEδ-Targeting PROTACs that Impair Lipid Metabolism
    Winzker, Michael
    Friese, Alexandra
    Koch, Uwe
    Janning, Petra
    Ziegler, Slava
    Waldmann, Herbert
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2020, 59 (14) : 5595 - 5601
  • [44] Computational methods and key considerations for in silico design of proteolysis targeting chimera (PROTACs)
    Abbas, Amr
    Ye, Fei
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 277
  • [45] Current advances and development strategies of orally bioavailable PROTACs
    Zeng, Shenxin
    Ye, Yingqiao
    Xia, Heye
    Min, Jingli
    Xu, Jiamei
    Wang, Zunyuan
    Pan, Youlu
    Zhou, Xinglu
    Huang, Wenhai
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 261
  • [46] Recent advances in the development of EGFR degraders: PROTACs and LYTACs
    Hong, Dawei
    Zhou, Bizhong
    Zhang, Bei
    Ren, Hao
    Zhu, Liquan
    Zheng, Guowan
    Ge, Minghua
    Ge, Jingyan
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 239
  • [47] PROTACs reach clinical development in inflammatory skin disease
    Ferguson, Fleur M.
    NATURE MEDICINE, 2023, 29 (12) : 3006 - 3007
  • [48] PROTACs: A novel strategy for cancer drug discovery and development
    Han, Xin
    Sun, Yi
    MEDCOMM, 2023, 4 (03):
  • [49] Development of a Data-Driven Predictive Model of Clothing Thermal Insulation Estimation by Using Advanced Computational Approaches
    Lee, Kyungsoo
    Choi, Haneul
    Choi, Joon-Ho
    Kim, Taeyeon
    SUSTAINABILITY, 2019, 11 (20)
  • [50] Development of a PDEδ-Targeting PROTACs that Impair Lipid Metabolism
    Winzker, Michael
    Friese, Alexandra
    Koch, Uwe
    Janning, Petra
    Ziegler, Slava
    Waldmann, Herbert
    Advanced Materials, 2020, 132 (14) : 5644 - 5650